

300436

2021015

2020

--	--	--	--

☐

√

√

☐

140,000,000

10

0

0

10

0

☐

√

1

			300436
	B 10 B 89	B 10 B 89	
	0591-38305305	0591-38305305	
	0591-38305333	0591-38305333	
	niuniu@cosunter.com	wangq@cosunter.com	

2

“ . ”

1
1.1
1

2020

2019 9

25

2019 12

2020

1

2020 4

421.19%

99.15%



2

2020

“ ”

“ ” “ ”

10,000

“ ”



1.2
1

TAF

“	”		TAF				25mg
TAF		300mg		TDF			
		2019 11	TAF		TAF		
			TAF			2020 12 15	
2							
	sofosbuvir	1				2017 9	
36170		2018					34494
			2019 8				
3					2020 12 14		
			(ED)				
				2019 7			
				2020 10 15			
	2021 3 25						
4			ED	(ED)		(BPH)	
2020 8							
2							
	2015 IPO						
1							
	GST-HG161						
		c-Met				c-Met	
GST-HG161		c-MET	2019 7 9	I		c-Met	
	c-Met		GST-HG161	900mg			
GST-HG161		PCT		GST-HG161		Ib/II	
							15
2							
			GST-HG151				
				GST-HG151	NASH		
			2019 4	GST-HG151			
GST-HG151		PCT				12	
3							
2015			“	”	GST-HG131/GST-HG121	GST-HG141	
					2017	AASLD	
EASL							
GST-HG141			HBVcccDNA		cccDNA		
						GST-HG141	
2019 11							
		I			I	PI	
Ia					Ib	CRO	GST-HG141
	PCT					14	

PI

PCT

创新药名称	临床前	临床申请	I期临床	II期临床	III期临床	生产注册申请
新型肝癌靶向药物GST-HG161	→					
可逆转创新药GST-HG151	→					
乙肝表面抗原抑制剂GST-HG141				→		
乙肝表面抗原抑制剂GST-HG131					→	
乙肝表面抗原抑制剂GST-HG121					→	

III

2

“ ”

3

25

2020 4

1

2023

2018

1,370 2008 240% 2023 1,400-1,700

2

2015 62.6%

3.9%

1

HBV

2017 2015 2.57

6.2% 1.15 88.7

2015 9% 8% 170

2019

5% 6% 7,000

2,000 3,000

2018 19% 11%

280 2015 170 2017 2016

80%

2

HCV

HCV 39.9 HCV 2015 7100

HCV 2019 560 HCV 2019 1,000

16.0153/10

1

2017 9

3

NAFLD

NASH NAFLD NAFLD 6.3 45 10 30 NASH NAFLD NAFLD

>25 NAFLD (HCC) HBV NASH NAFLD

NAFLD NASH

Discovery NASH 2025 Nature Reviews Drug 150

4

2018 9

26.67/10 23.31/10 36.5 31.9

(HCC)

5

drug-induced liver in jury DILI

TCM-NM-HP-DS

/

ADR 1100 DILI

NSAIDs

TCM-NM-HP-DS

DILI DILI DILI 23.80/10 DILI

3 20%

4

3

1

□ √

	2020	2019		2018
	368,489,433.97	414,866,330.97	-11.18%	402,400,221.06
	14,824,518.08	10,741,879.19	38.01%	16,484,410.89
	1,470,888.36	-3,534,179.57	141.62%	8,526,446.56
	15,597,456.96	33,988,140.40	-54.11%	10,943,959.05
/	0.1059	0.0767	38.07%	0.12
/	0.1056	0.0767	37.68%	0.12
	2.60%	2.08%	0.52%	3.17%
	2020	2019		2018
	1,005,780,979.42	895,878,350.99	12.27%	854,519,609.79
	576,597,504.24	565,575,598.98	1.95%	553,879,649.25

2

	83,370,350.33	89,866,687.33	97,554,206.23	97,698,190.08
	1,834,413.76	9,537,249.05	3,641,316.40	-188,461.13
	-569,897.55	4,050,842.01	1,310,663.08	-3,320,719.18
	6,549,411.26	-1,453,391.75	5,492,482.61	5,008,954.84

□ √

4

1

10


	16,037		14,992		0		0
10							
		15.98%	22,368,651		0		3,000,000
		9.72%	13,614,866		10,211,149		10,000,000
		9.67%	13,536,700		10,152,525		
		7.23%	10,125,000		0		
		5.36%	7,500,000		5,625,000		
19 E1		5.14%	7,200,000		0		
19 E2		3.93%	5,500,000		0		
		0.86%	1,210,000		0		
		0.72%	1,010,000		0		
		0.62%	870,000		0		
		1	19	E1 2019		19	E2
					2		

2

10

□

3



5

1

2020

1482.45

2020

38.01%

3.68

11.18%

1

OTC

2021 3 25

1

4

Dr.John Mao

CSCO

GST-HG161

I

900mg

Ia

Ib

PI

Ib/II

CRO

GST-HG121

2020

50

PCT

8

GST-HG141

GST-HG131

2020

OTC

421.19%

99.15%

BD

OTC

		1.62	4.06%	
		5%		92.5%
3				
2020 3				
	A		2,800	2,800
55,000.00				

6

□ √

7

1

√ □

2017 7 5 14 — 2017 [2017]22

2020 1 1

2020 1 1 2017 14 -

2020 1 1

2020

2

□ √

3

□ √